The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest ...

Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye ...

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Refractive cataract surgery has been transformed by advanced IOL technology, including extended and full-range vision lenses, ...

To create lasting change, ophthalmology must embrace the impact of sponsorship and advocacy—empowering the next generation of ...

An AI model for target IOP prediction performs as well as glaucoma specialists, offering a promising tool to enhance glaucoma ...

Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and ...

The acquisition also includes the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software ...

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.